# Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

> **NCT01870687** · PHASE3 · TERMINATED · sponsor: **Bionorica SE** · enrollment: 96 (actual)

## Conditions studied

- Premenstrual Syndrome
- Mastodynia

## Interventions

- **DRUG:** 20mg VAC BNO 1095 FCT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01870687
- **Lead sponsor:** Bionorica SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2016-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870687, "Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01870687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*